Johnson & Johnson (JNJ) Share-based Compensation Growth (1y) (2010 - 2026)
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Stock Comp. Growth (1y) (Qtr) |
| 1 |
Novartis Ag |
107,124,802.25 Bn |
107,124,802.25 Bn |
- |
- |
| 2 |
Eli Lilly |
969.00 Bn |
963.72 Bn |
16.22 Bn |
4.55% |
| 3 |
Johnson & Johnson |
539.46 Bn |
517.41 Bn |
15.96 Bn |
4.17% |
| 4 |
AbbVie |
376.92 Bn |
367.57 Bn |
10.78 Bn |
8.29% |
| 5 |
Merck |
285.00 Bn |
279.35 Bn |
12.09 Bn |
-5.13% |
| 6 |
Amgen |
177.58 Bn |
165.55 Bn |
5.87 Bn |
-11.76% |
| 7 |
Gilead Sciences |
163.22 Bn |
155.50 Bn |
5.52 Bn |
4.31% |
| 8 |
Pfizer |
145.86 Bn |
133.09 Bn |
-1.21 Bn |
60.00% |
| 9 |
Bristol Myers Squibb |
111.90 Bn |
101.44 Bn |
8.07 Bn |
1.39% |
| 10 |
Gsk |
88.34 Bn |
83.66 Bn |
- |
- |
| Date | Value |
| Mar 29, 2026 |
4.17% |
| Dec 28, 2025 |
29.83% |
| Sep 28, 2025 |
17.63% |
| Jun 29, 2025 |
20.23% |
| Mar 30, 2025 |
-4.64% |
| Dec 29, 2024 |
33.71% |
| Sep 29, 2024 |
-0.34% |
| Jun 30, 2024 |
-10.73% |
| Mar 31, 2024 |
-1.31% |
| Dec 31, 2023 |
-18.35% |
| Apr 2, 2023 |
10.07% |
| Apr 3, 2022 |
-9.45% |
| Oct 3, 2021 |
1.17% |
| Jul 4, 2021 |
8.59% |
| Apr 4, 2021 |
16.73% |
| Jan 3, 2021 |
0.00% |
| Sep 27, 2020 |
4.49% |
| Jun 28, 2020 |
3.82% |
| Mar 29, 2020 |
1.94% |
| Dec 29, 2019 |
2.56% |
| Sep 29, 2019 |
1.24% |
| Jun 30, 2019 |
0.64% |
| Mar 31, 2019 |
-3.73% |
| Dec 30, 2018 |
-23.53% |
| Sep 30, 2018 |
2.54% |
| Jul 1, 2018 |
6.48% |
| Apr 1, 2018 |
17.03% |
| Dec 31, 2017 |
1.49% |
| Apr 2, 2017 |
11.71% |
| Apr 3, 2016 |
0.49% |
| Sep 27, 2015 |
-1.46% |
| Jun 28, 2015 |
11.57% |
| Mar 29, 2015 |
3.03% |
| Dec 28, 2014 |
1.39% |
| Sep 28, 2014 |
27.95% |
| Jun 29, 2014 |
5.68% |
| Mar 30, 2014 |
2.06% |
| Dec 29, 2013 |
-2.04% |
| Sep 29, 2013 |
10.27% |
| Jun 30, 2013 |
16.84% |
| Mar 31, 2013 |
12.14% |
| Dec 30, 2012 |
0.00% |
| Apr 1, 2012 |
13.82% |
| Apr 3, 2011 |
-3.18% |
| Oct 3, 2010 |
6.96% |
| Jul 4, 2010 |
-18.68% |
| Apr 4, 2010 |
-1.26% |